HC Wainwright Issues Positive Forecast for NRIX Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Equities researchers at HC Wainwright lifted their Q1 2025 earnings per share (EPS) estimates for shares of Nurix Therapeutics in a research note issued on Wednesday, April 2nd. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.60) for the quarter, up from their previous estimate of ($0.72). HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ FY2025 earnings at ($2.88) EPS.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%.

A number of other research analysts have also weighed in on the company. Stephens reaffirmed an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, January 21st. JPMorgan Chase & Co. reduced their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partnrs upgraded Nurix Therapeutics to a “hold” rating in a research report on Monday, March 17th. Leerink Partners started coverage on shares of Nurix Therapeutics in a report on Monday, March 17th. They issued a “market perform” rating and a $16.00 target price for the company. Finally, Morgan Stanley upped their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, February 3rd. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, Nurix Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $30.88.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $9.69 on Monday. The company has a market cap of $738.73 million, a P/E ratio of -3.35 and a beta of 2.23. Nurix Therapeutics has a 52-week low of $9.45 and a 52-week high of $29.56. The firm’s fifty day moving average is $15.45 and its two-hundred day moving average is $19.86.

Institutional Investors Weigh In On Nurix Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NRIX. US Bancorp DE increased its position in shares of Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after acquiring an additional 842 shares during the period. GF Fund Management CO. LTD. bought a new position in Nurix Therapeutics in the fourth quarter worth approximately $28,000. Quarry LP increased its holdings in Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares during the period. Aquatic Capital Management LLC bought a new stake in Nurix Therapeutics during the 4th quarter valued at $87,000. Finally, Summit Investment Advisors Inc. raised its position in Nurix Therapeutics by 13.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock valued at $138,000 after purchasing an additional 877 shares in the last quarter.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the transaction, the chief financial officer now owns 39,549 shares in the company, valued at $785,047.65. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,326 shares of company stock worth $213,449. Insiders own 7.20% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.